MENLO PARK, Calif., Dec. 20, 2018 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ophthalmology and rare diseases, today announced the company will be participating in the...

MENLO PARK, Calif., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ophthalmology and rare diseases, today announced the appointment of Mike Fitzgerald as vice...

Results demonstrate single intravitreal administration of ADVM-022 gene therapy may provide a safe and effective long-term treatment option for wet AMD, potentially decreasing the need for frequent anti-VEGF injections MENLO PARK, Calif., Dec. 03, 2018 (GLOBE...

ADVM-022 is the first intravitreally delivered gene therapy utilizing directed evolution AAV.7m8 vector for wet AMD OPTIC trial to evaluate single administration of ADVM-022 for wet AMD Interim trial update expected by 1Q20 MENLO PARK, Calif., Nov. 19, 2018 (GLOBE...

MENLO PARK, Calif., Nov. 13, 2018 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ophthalmology and rare diseases, today announced the company will be participating in the...

MENLO PARK, Calif., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ophthalmology and rare diseases, today reported financial results for the third quarter ended...

Preliminary data from the ADVANCE Phase 1/2 Study in A1AT deficiency showed ADVM-043 in doses of up to 1.5 x 1013 vg/kg were safely administered and well tolerated; Protein expression did not meet a clinically meaningful level Company to provide update on rare...

MENLO PARK, Calif., Oct. 17, 2018 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases, today announced the promotion of Leone Patterson as the...

A single intravitreal injection of ADVM-022 in non-human primates (NHP) demonstrated durable expression of aflibercept sustained out to 22 months In an NHP model, ADVM-022 provided ocular expression of aflibercept at therapeutic levels equivalent to current standard...

ADVM-022 is a unique single-administration gene therapy delivered intravitreally for the treatment of wAMD OPTIC Phase 1 clinical trial initiation expected in 4Q18 MENLO PARK, Calif., Sept. 19, 2018 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a...